Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBNK-001 With or Without Pembrolizumab in Advanced Solid Tumors
NCT07410676Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EBNK-001 in solid tumor, sponsored by Essen BioTech. Primary endpoints: Incidence and severity of treatment-emergent adverse events and serious adverse events at 30 days and Incidence of Dose-Limiting Toxicities at 30 days. Started Feb 2026; status: recruiting.
02
Drugs
EBNK-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07410676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410676.